메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

유니세프와 르네상스, 터키 청소년 직업 교육 혁신 위한 협력 체결

이스탄불, 2025년 12월 2일 -- 터키를 기반으로 활동하는 건설•인프라 기업 르네상스 홀딩(Rönesans Holding)이 유니세프(UNICEF)의 '청소년 학습에서 수익 창출로(From Learning to Earning for Youth)' 프로그램의 주요 민간 부문 파트너로서 역할을 발표했다. 이 대담한 이니셔티브는 터키 전역 청소년을 위해 직업 교육을 재구상하고, 다음 세대가 번영하는 데 필요한 기술을 갖추도록 지원하기 위해 국가교육부(Ministry of National Education)와 협력해 추진될 예정이다. 야망과 기회의 가교 르네상스 홀딩은 이번 프로그램의 선도적 파트너로서 터키에서 가장 첨단 의료 시설 중 하나인 가지안테프 시립병원(Gaziantep City Hospital)을 120명의 보건 실업계 고등학생들에게 개방할 예정이다. 학생들은 교실을 벗어나 실제 현장에서 소프트웨어 개발, 식음료 서비스, 산업 유지보수와 수리, 배관과 에너지 시스템, 산업 자동화 기술 등 다양한 실무 경험을 쌓을 기회를 얻게 된다. 이 이니셔티브는 교육을 이처럼 현대 직장 수요와 직접
- 황정호 기자
- 2025-12-02 22:52
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025

Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 studies at the Radiological Society of North America (RSNA) 2025 Annual Meeting. Spanning screening mammography, digital breast tomosynthesis (DBT), breast density science, and risk modeling, this year's program represents one of the company's most extensive evidence portfolios to date. Lunit will exhib
- 김갑성 기자
- 2025-12-02 22:10
Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health

SEOUL, South Korea, Dec. 2, 2025 -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a significant step in Yuyu Pharma's plan to become a more active global player in the fast-growing animal health sector. Dalan is recognized for delivering the world's first USDA-approved honeybee vaccine and is now advancing a first-in-class shrimp vaccine aimed at transforming disease
- 김갑성 기자
- 2025-12-02 22:00
L&C Bio's 'Re2O' Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch

[ 메디채널 김갑성 기자 ] – Surging global demand drives rapid adoption across domestic and international medical sectors – SEONGNAM, South Korea, Dec. 2, 2025 -- L&C Bio (KOSDAQ: 290650, Co-CEOs Hwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its premium regenerative solution Re2O (ReCM, ECM: Extra Cellular Matrix) has rapidly emerged as a signature K-Medical tour procedure among international customers within just one year of its launch. Re2O is demonstrating robust sales growth and rapidly expanding its market presence among i
- 김갑성 기자
- 2025-12-02 22:00
Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business -- To Accelerate U.S. Market

Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.ai To strengthen revenue growth of AI-based brain imaging solutions in the North American market and expand product deployment across healthcare institutions SEOUL, South Korea, Dec. 2, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 2nd that it has appointed Josh Cohen, a veteran executive from leading global medical device companie
- 김갑성 기자
- 2025-12-02 22:00
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

[ 메디채널 김갑성 기자 ] AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. A Superior Dual-Action Mechanism: The novel PROTAC, D16-M1P2, employs a powerful dual-action mechanism that simultaneously degrades and inhibits the cancer-driving PKMYT1 protein, resulting in a more potent, selective, and durable therapeutic effect than traditional inhibitors. Strong P
- 김갑성 기자
- 2025-12-02 22:00
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary sh
- 김갑성 기자
- 2025-12-02 22:00
Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American Customer Value Leadership Recognition for Excellence in Patient-Centered Care Delivery

[ 메디채널 김갑성 기자 ] Frost & Sullivan recognizes Health Recovery Solutions for delivering adaptable, outcomes-driven, technology-enabled longitudinal care models SAN ANTONIO, Dec. 2, 2025 -- Frost & Sullivan is pleased to announce that Health Recovery Solutions (HRS) has received the 2025 North American Customer Value Leadership Recognition in the longitudinal care models sector for its outstanding achievements in system efficiency, sustainable program outcomes, and long-term client value. This recognition highlights HRS's consistent leadership in delivering measurable improvement
- 김갑성 기자
- 2025-12-02 21:30
Global Fitness Leader Anytime Fitness Accelerates Asia Expansion with New Regional Agents for Taiwan

TAIPEI, Dec. 2, 2025 -- Anytime Fitness, the world's largest and fastest-growing fitness franchise, continues its momentum across Asia with significant new developments. With more than 5,600 clubs across 40 countries and on all seven continents, the brand remains unmatched in global presence and accessibility. In Asia, growth is driven by Inspire Brands Asia (IBA), the exclusive regional master franchisee for Singapore, Malaysia, Thailand, Taiwan region, the Philippines, Vietnam, Hong Kong SAR, and Indonesia. With a rapidly expanding network of over 520 clubs, the region is now
- 노기식 기자
- 2025-12-02 21:09
Health In Tech Announces Voluntary Extension of Lock-Up Period

STUART, Fla., Dec. 2, 2025 -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced that its executive management team, vice presidents across functions, and Board of Directors have voluntarily agreed to extend the lock-up restrictions on all shares they hold for an additional six months beyond the original twelve-month lock-up established at the time of the Company's final prospectus issued in connection with its initial public offering on December 20, 2024. Under this voluntary extension, all shares hel
- 김갑성 기자
- 2025-12-02 21:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분